Toray Develops Porous Fiber Technology for Adsorbing Pathogenic Substances in Intractable Diseases
Toray has developed a technology to control the pore size of PMMA porous fibers up to 1,000nm, enabling the selective removal of high-molecular-weight pathogenic substances. The technology aims to provide new blood purification treatment options for intractable diseases such as autoimmune disorders and cancer.
📋 Article Processing Timeline
- 📰 Published: March 26, 2026 at 23:14
- 🔍 Collected: March 28, 2026 at 21:59 (46h 45m after Published)
- 🤖 AI Analyzed: April 15, 2026 at 02:48 (412h 48m after Collected)
Toray Industries, Inc. announced the development of a technology that allows for the arbitrary control of pore sizes in polymethyl methacrylate (PMMA) porous fibers, ranging from several nanometers to approximately 1,000nm. This breakthrough enables the selective adsorption and removal of high-molecular-weight pathogenic substances, such as autoantibodies, lipoproteins, and exosomes, which were previously difficult to capture. The company intends to advance the design and mass production of these fibers for blood purification therapies for intractable diseases, including autoimmune disorders, cardiovascular metabolic diseases, neurodegenerative diseases, and cancer. Additionally, applications in biopharmaceutical manufacturing are being explored.
FAQ
What types of diseases can this technology help treat?
It is intended for blood purification therapies for intractable diseases such as autoimmune disorders, cardiovascular metabolic diseases, neurodegenerative diseases, and cancer.
How does it differ from conventional fibers?
It enables control of pore sizes up to approximately 1,000nm, which is more than 50 times larger than conventional capabilities, allowing for the removal of previously uncapturable high-molecular-weight pathogenic substances.